viewSyncona Limited

Syncona notes portfolio company Freeline Therapeutics announces IPO pricing

The gene therapy group will list on the Nasdaq Global Select Market on Friday with its shares priced at US$18 each


Syncona Ltd (LON:SYNC) noted that its portfolio firm, gene therapy group Freeline Therapeutics Holdings PLC, has announced the pricing of its initial public offering (IPO) to list this Friday on the Nasdaq Global Select Market.

Freeline has priced its IPO shares at US$18 each to raise gross proceeds of around US$158.8mln (£120.8mln). Syncona said it will invest US$24.3mln (£18.5mln) in the IPO and will remain Freeline’s largest investor with a 49% stake in the business.

READ: Syncona slips as NAV hit by Autolus share price fall

The IPO also values Syncona’s stake at around £257.7mln compared to £181.5mln as reported at June 30, 2020.

"In the five years since Syncona founded Freeline, the company has brought multiple programmes to the clinic, with a cutting-edge manufacturing platform and expert management team”, Chris Hollowood, Syncona’s chief investment officer said in a statement.

“Today's milestone is a significant achievement for the business, and we look forward to continuing to work in close partnership with the management team as it looks to realise its ambition to deliver treatments to patients", he added.

Syncona shares were 1.1% lower at 254p in early deals on Friday.

Quick facts: Syncona Limited

Price: 249.4107 GBX

Market: LSE
Market Cap: £1.66 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Open Orphan signs UK government contract to development COVID-19 Human...

Open Orphan's (LON:ORPH) Chairman Cathal Friel talks to Proactive London after announcing a contract with the UK Government for the development of a COVID-19 human challenge study model. Friel explains that the company, hVIVO, is the world's leader in this sector, having safely run more human...

26 minutes ago

2 min read